A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer

Summary

The study is divided into two phases: dose escalation and dose extension. The dosing regimens include a single-dose study and a multiple-dose study. It adopts a single-center, open-label, non-randomized, single-arm clinical trial design, where patients with advanced malignant cancer are selected to orally take TQB3117 tablets. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TQB3117 tablets in patients.

Timeline

Start

2024-06

Primary completion

2025-06

Completion

2026-08

Drugs

Indications